2 research outputs found
Ligand-selective small molecule modulators of the constitutively active vGPCR US28
US28 is a broad-spectrum constitutively active G protein-coupled receptor encoded by the human
cytomegalovirus (HCMV). It binds and scavenges multiple CC-chemokines as well as CX3CL1 (fractalkine)
by constitutive receptor endocytosis to escape immune surveillance. We herein report the design and
characterization of a novel library of US28-acting commercially available ligands based on the molecular
descriptors of two previously reported US28-acting structures. Among these, we identify compounds
capable of selectively recognizing CCL2-and CCL4-, but not CX3CL1-induced receptor conformations.
Moreover, we find a direct correlation between the binding properties of small molecule ligands to CCLinduced conformations at the wild-type receptor and functional activity at the C-terminal truncated
US28D300. As US28D300 is devoid of arrestin-recruitment and endocytosis, this highlights the potential
usefulness of this construct in future drug discovery efforts aimed at specific US28 conformations. The
new scaffolds identified herein represent valuable starting points for the generation of novel anti-HCMV
therapies targeting the virus-encoded chemokine receptor US28 in a conformational-selective manne
Molecular dynamics-guided discovery of an ago-allosteric modulator for GPR40/FFAR1
The long-chain fatty acid receptor FFAR1/GPR40 binds agonists in both an interhelical site between the extracellular segments of transmembrane helix (TM)-III and TM-IV and a lipid-exposed groove between the intracellular segments of these helices. Molecular dynamics simulations of FFAR1 with agonist removed demonstrated a major rearrangement of the polar and charged anchor point residues for the carboxylic acid moiety of the agonist in the interhelical site, which was associated with closure of a neighboring, solvent-exposed pocket between the extracellular poles of TM-I, TM-II, and TM-VII. A synthetic compound designed to bind in this pocket, and thereby prevent its closure, was identified through structure-based virtual screening and shown to function both as an agonist and as an allosteric modulator of receptor activation. This discovery of an allosteric agonist for a previously unexploited, dynamic pocket in FFAR1 demonstrates both the power of including molecular dynamics in the drug discovery process and that this specific, clinically proven, but difficult, antidiabetes target can be addressed by chemotypes different from existing ligands